Anti-NLRP1b (mouse), mAb (2A12)

The NLRP1 inflammasome is a multiprotein complex that is a potent activator of inflammation. As inflammasome-forming sensor protein, NLRP1b, upon detection of microbial molecules or pathogen-encoded activities, serves as a platform for the recruitment and activation of proinflammatory caspases including caspase-1 through a caspase activation and recruitment domain (CARD). Active caspase-1 mediates the maturation and release of the proinflammatory cytokines interleukin IL-1beta and IL-18. Mouse NLRP1b can be activated through proteolytic cleavage by the bacterial Lethal Toxin (LeTx) protease, resulting in degradation of the N-terminal domains of NLRP1b and liberation of the bioactive C-terminal domain, which includes the caspase activation and recruitment domain (CARD). NLRP1b has an unusual domain architecture, containing a CARD at its C-terminus rather than the N-terminus like all other inflammasomes, and a function-to-find domain (FIIND), which is located between the LRRs and CARD. The FIIND undergoes a constitutive self-cleavage event, such that NLRP1b exists in its non-activated state as two, noncovalently associated polypeptides, the N-terminal domains and the C-terminal CARD-containing fragment. Inflammasome activation is the result of site-specific cleavage in the N-terminus of mouse NLRP1b by the Lethal Factor (LF) protease subunit of LeTx, which results in its activation. Upon cleavage by LF, a novel N-terminus is formed, which is then targeted for proteasomal degradation by a protein quality control mechanism called the 'N-end rule' pathway. Since the proteasome is a processive protease, it progressively degrades the N-terminal domains of NLRP1b but is disengaged upon arriving at the self-cleavage site within the FIIND domain. Degradation of the N-terminal domains thus releases the bioactive C-terminal CARD-containing fragment of NLRP1b, which is sufficient to initiate downstream inflammasome activation. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.